Repligen jumps after Q1 beat and higher 2026 adjusted EPS outlook
Repligen shares rose after the company reported Q1 2026 revenue of about $194 million (+15% reported, +11% organic) and adjusted EPS of $0.48. Management raised full-year 2026 adjusted EPS guidance to $1.97–$2.05 while reiterating organic revenue growth guidance of 9%–13%.
1. What’s moving the stock
Repligen Corp. (RGEN) is trading higher as investors react to the company’s first-quarter 2026 earnings release and updated outlook. The key catalyst is a profit outlook increase: Repligen lifted its full-year 2026 adjusted diluted EPS guidance to $1.97–$2.05 while keeping its FY26 organic revenue growth outlook unchanged at 9%–13%. (globenewswire.com)
2. The quarter in numbers
For Q1 2026 (ended March 31, 2026), Repligen posted revenue of roughly $194 million (about +15% year over year reported, +11% organic). GAAP diluted EPS was $0.15 and adjusted diluted EPS was $0.48, up from $0.39 a year earlier—an earnings result that helped outweigh investor concerns around any modest top-line variability. (stocktitan.net)
3. Guidance and what investors are focusing on next
With revenue growth guidance reiterated but adjusted EPS increased, the market is reading the update as a sign of improving profitability, operating leverage, and cost discipline. Focus now shifts to whether demand trends remain steady across bioprocessing workflows through the rest of 2026 and whether the company can continue expanding margins while delivering within the maintained 9%–13% organic growth range. (globenewswire.com)